The efficacy of OM-MOG in preventing CNS-directed migration of these cells while retaining their rapid activation and presence in the periphery elucidates a novel immune tolerance mechanism, emphasizing the potential of targeting circulating CCR2+Ly6Chi monocyte maturation as a therapeutic strategy for autoimmune CNS diseases like MS [19]. This evidence concerns the gene CCR2 and myeloid sarcoma.